Last updated: 2026-09-05 22:20:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Ensysce Biosciences, Inc. (ENSC) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.46, with a market capitalization of $8.62M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.23 to $2.75. This page covers its latest market performance, valuation, price trends and company information.
$8.62M | |
$0.44 | |
$61,632.00 | |
$0.23 | |
$0.44 | |
515.61K | |
-- | |
-- | |
$2.75 | |
$0.23 | |
-- | |
-- |
Ensysce Biosciences, Inc. (ENSC) last closed at $0.44 as of 2026-09-05 00:00:00, unchanged from the previous close of $0.44.
During the latest regular trading session, ENSC traded between $0.23 and $61,632.00, with a volume of 515.61K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Ensysce Biosciences, Inc. (ENSC) moved from $0.39 to $0.46, representing a gain of 17.18% ($0.07).
The stock traded between $0.42 and $0.46 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 598.57 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 9.0%
ENSC is currently trading at $0.46, placing it 9.0% of the way from its 52-week low of $0.23 to its 52-week high of $2.75. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 10 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Ensysce Biosciences, Inc. (ENSC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.